30 January 2021: Clinical Research
Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
Naibo Hu 12DE , Tiejun Qin 1B , Xiaoyan Du 3C , Bingyi Wang 3DE , Xiaoyun Wang 3E , Zefeng Xu 1DF , Lijuan Pan 1F , Shiqiang Qu 1DF , Zhijian Xiao 1A*DOI: 10.12659/MSM.928454
Med Sci Monit 2021; 27:e928454
Table 1 Baseline patient characteristics.
| Indicators | Total (n=158) | Azacitidine group (n=38) | Decitabine | P value |
|---|---|---|---|---|
| 59 [49–66] | 63 [53–68] | 57 [49–64] | 0.024* | |
| 0.699 | ||||
| Male | 101 (63.9%) | 23 (60.5%) | 78 (65.0%) | |
| Female | 57 (36.1%) | 15 (39.5%) | 42 (35.0%) | |
| Hypertension | 12 (7.6%) | 0 | 12 (10.0%) | 0.071 |
| Coronary heart disease | 8 (5.1%) | 2 (5.3%) | 6 (5.0%) | 1.000 |
| Diabetes mellitus | 11 (7.0%) | 2 (5.3%) | 9 (7.5%) | 1.000 |
| Hepatitis | 5 (3.2%) | 1 (2.6%) | 4 (3.3%) | 1.000 |
| Tuberculosis | 3 (1.9%) | 1 (2.6%) | 2 (1.7%) | 0.564 |
| 0.450 | ||||
| MDS-EB1 | 63 (39.9%) | 14 (36.8%) | 49 (40.8%) | |
| MDS-EB2 | 72 (45.6%) | 16 (42.1%) | 56 (46.7%) | |
| MDS-MLD/RS/U | 23 (14.6%) | 8 (21.1%) | 15 (12.5%) | |
| 0.154 | ||||
| Good | 78 (49.4%) | 24 (63.2%) | 54 (45.0%) | |
| Intermediate | 45 (28.5%) | 7 (18.4%) | 38 (31.7%) | |
| Poor | 35 (22.2%) | 7 (18.4%) | 28 (23.3%) | |
| 0.341 | ||||
| Intermediate-1 | 64 (40.5%) | 19 (50.0) | 45 (37.5%) | |
| 6Intermediate-2 | 63 (39.9%) | 14 (36.8%) | 49 (40.8%) | |
| High | 31 (19.6%) | 5 (13.2%) | 26 (21.7%) | |
| 0.383 | ||||
| Low | 16 (10.1%) | 5 (13.2%) | 11 (9.2%) | |
| Intermediate | 33 (20.9%) | 11 (28.9%) | 22 (18.3%) | |
| High | 53 (33.5%) | 10 (26.3%) | 43 (35.8%) | |
| Very high | 56 (35.4%) | 12 (31.6%) | 44 (36.7%) | |
| 0.449 | ||||
| 39 (24.7%) | 10 (26.3%) | 29 (24.2%) | ||
| ≥5 | 98 (62.0%) | 21 (55.3%) | 77 (64.2%) | |
| >15 | 21 (13.3%) | 7 (18.4%) | 14 (11.7%) | |
| 108 (68.4%) | 21 (55.3%) | 87 (72.5%) | 0.070 | |
| WBC, 10/L | 1.9 [1.2–3.7] | 1.4 [1.1–2.9] | 2.0 [1.4–4.0] | 0.024* |
| RBC, 10/L | 2.5 [2.2–3.0] | 2.6 [2.2–3.1] | 2.5 [2.2–3.0] | 0.901 |
| Hb, g/L | 80.0 [70.0–93.0] | 78.0 [68.0–91.8] | 80.0 [70.0–93.0] | 0.828 |
| ANC,10/L | 0.6 [0.3–1.3] | 0.8 [0.3–1.5] | 0.6 [0.3–1.2] | 0.378 |
| PLT, 10/L | 42.0 [21.0–86.0] | 38.0 [21.0–85.8] | 42.0 [22.5–88.5] | 0.855 |
| LY, 10/L | 0.9 [0.7–1.3] | 0.8 [0.5–1.2] | 1.0 [0.7–1.3] | 0.038* |
| Mono, 10/L | 0.1 [0.1–0.4] | 0.2 [0.1–0.3] | 0.1 [0–0.4] | 0.877 |
| Ret, 10/L | 0.03 [0.01–0.10] | 0.04 [0.01–0.08] | 0.04 [0.01–0.06] | 0.358 |
| Ret% | 1.3 [0.6–2.6] | 1.9 [0.6–3.3] | 1.3 [0.6–2.4] | 0.123 |
| IGs, 10/L | 0.02 [0.01–0.14] | 0.02 [0.01–0.10] | 0.02 [0–0.14] | 0.758 |
| IRF, % | 16.0 [10.1–23.0] | 15.8 [9.0–23.2] | 16.0 [10.3–22.7] | 0.874 |
| NRBC, 10/L | 0.01 [0–0.04] | 0.01 [0–0.03] | 0.01 [0–0.04] | 0.985 |
| 18 [8–102] | 22 [6–296] | 16 [8–74] | 0.361 | |
| 117 (74.1%) | 21 (55.3%) | 96 (80.0%) | 0.005* | |
| 96 (60.8%) | 17 (44.7%) | 79 (65.8%) | 0.023* | |
| Parametric continuous variables presented as mean (SD); nonparametric variables reported as median [IQR]; categorical variables represented as number (percentage within category). * ANC – absolute neutrophil count; BM – bone marrow; Hb – hemoglobin; IGs – immature granulocytes; IPSS – International Prognostic Scoring System; IPSS-R – Revised International Prognostic Scoring System; IRF – immature reticulocyte fraction; LY – lymphocyte count; Mono – monocyte count; MDS-EB1 – MDS with excess blasts 1; MDS-EB2 – MDS with excess blasts 2; MDS-MLD/RS/U – MDS multilineage dysplasia/ring sideroblasts/unclassifiable; NRBC – nucleated red blood cells; PLT – platelet count; RBC – red blood cell count; Ret – reticulocyte count; WBC – white blood cells. | ||||